Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.

Anchorstone Holdings Limited

基石控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1592)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Director(s)**") of Anchorstone Holdings Limited (the "**Company**") is pleased to announce that with effect from 10 December 2025, Prof. Jiang Zhihong ("**Mr. Jiang**") has been appointed as an independent non-executive Director. The biographical details of Mr. Jiang are set out below:

Prof. Jiang Zhihong (姜志宏)

Prof. Jiang, aged 57, is currently the Vice President and Chair Professor of Macau University of Science and Technology, as well as the Director of the State Key Laboratory of Mechanism and Quality of Chinese Medicine. Prof. Jiang obtained his PhD in Pharmaceutical Sciences from Nagasaki University in Japan and conducted postdoctoral research at the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School in the United States.

Since 2001, Prof. Jiang joined School of Chinese Medicine, Hong Kong Baptist University in 2001 as an assistant professor, and was promoted to be an associate professor in 2005 and full professor in 2008. In July 2011, he became the Dean of the Macau Institute of Pharmaceutical and Health Applications, and Deputy Director of State Key Laboratory for Quality Research in Chinese Medicines (Macau University of Science and Technology). Prof. Jiang has over 30 years of experience in natural product chemistry and Chinese medicine quality research. He has published more than 320 SCI-indexed academic papers and serves as a member of the Chinese Pharmacopoeia Commission and an editorial board member of multiple international journals

Prof. Jiang has entered into a letter of appointment with the Company for an initial term of three years commencing from 10 December 2025 unless terminated by not less than one month's prior notice in writing served by either party to the other. Prof. Jiang is subject to retirement by rotation and re-election in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the articles of association of the Company. Prof. Jiang's annual remuneration shall be HK$120,000, which was agreed between the Company and Prof. Jiang and reviewed and approved by the remuneration committee of the Company (the "**Remuneration Committee**") and the Board with reference to Prof. Jiang's roles and responsibilities with the Company and prevailing market conditions. Prof. Jiang shall hold office until the first general meeting of the Company after her appointment, at which he shall be eligible for re-election.

As at the date of this announcement, save as disclosed above, Prof. Jiang has confirmed that he (i) does not have any other relationship with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iii) does not hold any other position with the Company and other members of the Group, nor any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement or other major appointments and professional qualifications. Save as disclosed above, there is no other information in relation to the appointment Prof. Jiang that is required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warm welcome to Prof. Jiang.

By Order of the Board
Anchorstone Holdings Limited
Don Mun Min
Company Secretary

Hong Kong, 10 December 2025.

As at the date of this announcement, the Executive Directors are Mr. Lui Yue Yun Gary and Ms. Lui Natalie Po Wai, and the Independent Non-executive Directors are Mr. Ko Tsz Kin and Mr. Wong Yue Fai.